Sugi Predict

Sugi Predict / Compounds / SCHEMBL371765

SCHEMBL371765

SCHEMBL371765

COc1cc2ncnc(-c3c(N)ccc(N)c3F)c2cc1OC

nearest known ligand 0.67

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ KIT P10721 4/20 0.67
▸ EGFR P00533 7/20 0.46
▸ TRPA1 O75762 1/20 0.46
▸ ACHE P22303 1/20 0.45
▸ BACE1 P56817 1/20 0.45
▸ PDE10A Q9Y233 1/20 0.45
▸ KDR P35968 6/20 0.44
▸ RET P07949 4/20 0.44
▸ FLT1 P17948 2/20 0.44
▸ KIF5B P33176 3/20 0.44
▸ FGFR1 P11362 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2926080 0.84 KIT (0.67) KITEGFRTRPA1PDE10AKDR
SCHEMBL4974935 0.83 KIT (0.58) KITEGFRACHEBACE1KDR
SCHEMBL15516134 0.80 KIT (1.00) KITEGFRTRPA1KDRRET
SCHEMBL15504611 0.75 KIT (1.00) KITEGFRTRPA1KDRRET
SCHEMBL5665515 0.75 KIT (0.58) KITEGFRACHEBACE1KDR
SCHEMBL5569432 0.74 KIT (0.69) KITEGFRKDRRETFLT1
SCHEMBL1012376 0.74 TRPA1 (0.63) KITEGFRTRPA1KDRRET
SCHEMBL6182448 0.72 KIT (0.78) KITEGFRTRPA1KDRFLT1
SCHEMBL5568255 0.71 KIT (0.64) KITEGFRKDRRETFLT1
SCHEMBL27478273 0.71 EGFR (0.55) KITEGFRTRPA1PDE10AKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP disclosed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US disclosed
EP-3329918-A2 C-MET MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2018-06-06 — — EP disclosed
EP-2409704-B1 c-Met modulators and methods of use EXELIXIS INC (US) 2017-09-20 — — EP disclosed
US-20160185725-A1 c-Met Modulators and Method of Use EXELIXIS, INC. 2016-06-30 — — US disclosed
US-20150376133-A1 C-Met Modulators and Methods of Use EXELIXIS, INC. 2015-12-31 — — US disclosed
US-9174947-B2 c-Met modulators and methods of use Exelixus, Inc. (US) 2015-11-03 — — US disclosed
US-20140155396-A1 C-Met Modulators and Method of Use EXELIXIS, INC. 2014-06-05 — — US disclosed
US-20140155378-A9 c-Met Modulators and Method of Use EXELIXIS, INC. (US) 2014-06-05 — — US disclosed
EP-2392565-B1 c-Met modulators and methods of use EXELIXIS INC (US) 2014-03-19 — — EP disclosed
US-20090170896-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2009-07-02 — — US disclosed
US-20090105299-A1 c-MET MODULATORS AND METHODS OF USE EXELIXIS, INC (US) 2009-04-23 — — US disclosed
EP-1673085-A4 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2008-12-10 — — EP disclosed
WO-2008035209-A2 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY METHYLGENE INC. (CA) 2008-03-27 — — WO disclosed
US-20080004273-A1 Inhibitors of protein tyrosine kinase activity METHYLGENE, INC. (CA) 2008-01-03 — — US disclosed
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-10-18 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
EP-1673085-A2 C-MET MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2006-06-28 — — EP disclosed
WO-2005030140-A2 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-04-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET KIT 5/4885EGFR 124/4885TRPA1 3530/4885
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET KIT 5/4885EGFR 124/4885TRPA1 3530/4885
US-20140155378-A9 c-Met Modulators and Method of Use FLT4, MET, FLT1 KIT 4/4885EGFR 181/4885TRPA1 4142/4885
US-20140155396-A1 C-Met Modulators and Method of Use FLT4, MET, FLT1 KIT 4/4885EGFR 181/4885TRPA1 4142/4885
US-20150376133-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET KIT 5/4885EGFR 124/4885TRPA1 3530/4885
US-20090170896-A1 c-Met modulators and methods of use FLT4, MET, FLT1 KIT 4/4885EGFR 166/4885TRPA1 4179/4885
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 KIT 4/4885EGFR 181/4885TRPA1 4142/4885
US-20160185725-A1 c-Met Modulators and Method of Use FLT4, MET, FLT1 KIT 4/4885EGFR 181/4885TRPA1 4142/4885
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 KIT 4/4885EGFR 181/4885TRPA1 4142/4885
US-20090105299-A1 c-MET MODULATORS AND METHODS OF USE FLT4, MET, FLT1 KIT 4/4885EGFR 166/4885TRPA1 4179/4885
US-20080004273-A1 Inhibitors of protein tyrosine kinase activity HGF, ERBB2, MET KIT 355/4885EGFR 6/4885TRPA1 4312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.